At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
OCEA Ocean Biomedical
Trading 11-22 12:23:55 EST
0.7365
+0.0235
+3.30%
High0.7600
Low0.6950
Vol29.74K
Open0.7000
D1 Closing0.7130
Amplitude9.12%
Mkt Cap25.52M
Tradable Cap5.54M
Total Shares34.65M
T/O21.87K
T/O Rate0.40%
Tradable Shares7.52M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Ocean Biomedical Inc - Michelle Berrey to Act as Interim Chief Executive Officer
BRIEF-Molecure (Wse Moc) And Nasdaq-Listed Biotechnology Company Ocean Biomedical (Nasdaq Ocea) Sign An Exclusive Licensing Agreement For The Development And Commercialization Of Selective Ykl-40 Inhibitors
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses
Ocean Biomedical, Inc. (Nasdaq: Ocea) Announces Patent Issued for Pfgarp Malaria Antibodies Central to Company’s Malaria Treatment and Prevention Platforms
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company’s Malaria Treatment and Prevention Platforms
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP. The company is based in Providence, Rhode Island. Ocean Biomedical, Inc. operates as a subsidiary of Poseidon Bio, LLC.